Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FJORD phase 3 trial of benralizumab in bullous pemphigoid
MOH_2021-06-02_010018Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Bullous Pemphigoid (BP) comparing Benralizumab with Placebo (2 arms). Primary endpoint: Primary endpoint not provided. Planned start Mar 2021; status: not yet recruiting.
02
Drugs
benralizumab
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on MOH_2021-06-02_010018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-06-02_010018.